( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57



Dr. Vijant Singh Chandail* and Dr. Vinu Jamwal


Introduction: Ulcerative colitis and Crohn’s disease are immune mediated inflammatory bowel disease (IBD) which affects the gastrointestinal tract with several extraintestinal manifestations. Hepatic manifestations in IBD vary and range from benign disorders, such as fatty liver to end-stage hepatic failure. Non alcoholic fatty liver disease (NAFLD) is deemed to be hepatic manifestation of metabolic syndrome which is cluster of central obesity, hypertension, hypertriglyceridemia and low HDL. NAFLD is the most common chronic liver disease, characterized by the presence of steatosis in > 5% of the hepatocytes and whose prevalence is steeply increasing in parallel with obesity[1] NAFLD includes a wide spectrum of disorders, ranging from hepatic steatosis (NAFL) to non-alcoholic steatohepatitis (NASH). NAFLD patients are at high risk for liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC).[1,5] The prevalence of NAFLD in IBD patients is highly variable ranging from 1.5% to even 40%, in dependence of different diagnostic criteria.[6,8] Despite IBD is commonly considered a wasting disease characterized in some cases by malabsorption and severe weight loss, recent data indicate that the prevalence of NAFLD among IBD patients is increased as compared to the general population.[9] IBD patients develop NAFLD with fewer metabolic risk factors than general population.[6] Materials and methods. This retrospective analysis was conducted in IBD patients on regular follow up at the Gastroenterology division of the Department of Medicine w.e.f March 2018 to December 2019. The patients were evaluated with detailed clinical history, medical examination and blood investigations. Included were patients with age group of 18 -60 years with biopsy proven diagnosis of Idiopathic ulcerative colitis or Crohns disease. Exclusion criteria included patients with alcohol intake in excess of 20 grams per day, history of jejunoileal bypass surgery or extensive small bowel resection, type 2 diabetes mellitus, usage of drugs known to cause secondary steatosis like corticosteroids, methotrexate, and amiodarone. Results: A total of 236 patients were included in the study, out of which 45 were excluded as per the exclusion criteria and only 191 patients participated in the study design. Out of 191 patients, 158(83%) were identified as having idiopathic ulcerative colitis (IUC) and and 33(17%) had Crohns disease (CD). There was no significant difference in the IUC and CD patients when assessed separately, so both the groups were considered together. The prevalence of NAFLD was 55.5%(106/191) in our study group, with grade 1 hepatic steatosis in 61 out of 106 (57.5%), grade 2 steatosis in 27 out of 106 (25%), and grade 3 steatosis in 18 out of 106 patients (17.5%). Conclusion: Our study concludes that the prevalence of NAFLD in IBD is very high (55.5%) and regular follow up of the IBD patients for the development of NAFLD is the need of the hour, in order to prevent the further complications of NAFLD.

Keywords: Non-alcoholic fatty liver disease, inflammatory bowel disease, Ultrasonography.

[Full Text Article] [Download Certificate]


  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44



  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 June 2024 Issue has been Published, Kindly check it on


    JUNE 2024 issue has been successfully launched on JUNE 2024.

  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia